Sherwin Williams

SHW

----

2026-W382026-09-14

SHW.US Weekly Report · 2026-W38

Sherwin Williams edged down 0.8% this week to close at 320.73 USD, yet strong fundamentals remain evident. Q2 earnings growth hit 14.3% year-over-year, valuation sits at the 11th percentile in a five-year range—historically cheap—and institutional sentiment is densely bullish (24 of 27 ratings are buy-or-above). Net capital inflow persists. The critical tension worth watching: current PE of 28.96x sits far above the industry median of 18.88x, suggesting the market still prices in substantial earnings power growth, yet whether the 391 USD consensus target (21.9% upside) is achievable hinges on the consistency of this expansion narrative in coming quarters.

Price Action

This week closed at 320.73 USD versus last week’s 323.31 USD, a decline of 0.80%. Intra-week range was tight—2.2% amplitude (high 321.39, low 314.38)—pointing to consolidation behavior. Weekly volume totaled 9.05 million shares (daily average ~1.81 million), in line with the 60-day median; no extreme volume expansion or contraction noted. Since early September, the stock has oscillated within a 315–330 USD band; it currently sits at the mid-point, lacking clear directional conviction on either side.

Valuation and Earnings

Current P/E stands at 28.96x, placing it at the 11th percentile of its five-year distribution—a historical low point. However, this PE significantly exceeds the sector median of 18.88x, indicating the market still applies a relative premium to the company’s earnings capacity.

Q2 2026 reported EPS of 3.43 USD, representing 14.33% year-over-year growth and a 59.5% sequential jump from Q1’s 2.15 USD. Revenue reached 6.789 billion USD, up 7.52% YoY. Q2 ROE spiked to 81.45%, well above historical norms, signaling substantial capital-efficiency improvements. The Street’s consensus EPS median for 2026 stands at 12.84 USD; at the current share price, this implies a forward PE of ~25x, suggesting the market has priced in a measured near-term earnings acceleration rather than extraordinary growth.

Capital Flows

As of September 18, net capital inflow prevails. Retail investors (small orders) drove a net inflow of 306.43 million, mid-tier orders contributed 55.70 million, and institutional players (large orders) added only 1.64 million. The dominance of retail participation, with institutional restraint, is typical in rebound phases but warrants monitoring—it hints that large money remains circumspect on the valuation sustainability.

Institutional Sentiment

The rating distribution shows 12 strong buys, 12 holds, and 3 buys among 27 analysts—24 of whom are constructive. The consensus price target is 391 USD, implying 21.9% upside from the current 320.73 USD, and the company ranks first in the specialty chemicals cohort. Bear in mind that analyst ratings lag price action by weeks to months; recent capital flow dynamics may be more indicative of real-time conviction than a three-month-old report upgrade.

Weekly News Digest

Recent coverage clusters around valuation debate and rating momentum:

The narrative centers on whether the company’s valuation has already priced in growth expectations, and on a wave of analyst upgrades citing fundamental strength. Insider selling and modest institutional accumulation also appear, though in limited volumes. Overall, sentiment favors the earnings story, but conviction on valuation sustainability remains guarded.

Takeaway

The signals align in a nuanced way: valuation depth (low percentile PE) and bullish institutional ratings point toward upside potential, yet the elevated PE relative to sector median, combined with retail-dominated inflows and cautious institutional sizing, creates a paradox. The market is optimistic on earnings growth but unconvinced by current price levels—a tension evident in this week’s tight consolidation (0.8% loss, 2.2% range) and lack of sustained momentum in either direction. The next catalyst is likely Q3 earnings; if sequential and YoY growth confirm the expansion trajectory, institutional participation could accelerate and unlock the 391 USD target. For now, the stock’s sideways posture reflects a wait-and-see equilibrium.